anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:An adhesive application pharmaceutical prepared by incorporating a rubber type adhesive material with a drug active constituent and cysteine, and having improved stability of the drug active constituent. CONSTITUTION:An adhesive application pharmaceutical prepared by incorporating a rubber type adhesive plaster, e.g. a natural rubber, synthetic rubber or a mixture thereof and further the third constituent, e.g. a tackifier or an adhesion and holding power adjusting agent, with a drug active constituent and an additive selected from cysteine or a cysteine derivative, e.g. an alkyl ester of cysteine or cysteinamide, and a salt thereof having the thiol group in the free state. The amount of the additive to be incorporated is about 0.01-50% based on the weight of the adhesive plaster. A compound containing a phenolic hydroxyl group, e.g. a salicylic acid derivative or capsaicine, or an amine type compound, e.g. an ethanolamine type antihistaminic agent, used as the drug active constituent is particularly effective.
A method for determining the pathogenicity/benignity of a genomic variant in connection with a given disease is described. Such a method comprises the steps of accessing genomic data (D) comprising a list of the patient's genomic variants and then, for each variant detected, verifying (S1), by electronic computing means, whether or not the variant meets each of a plurality of predefined pathogenicity/benignity criteria. Each of such pathogenicity/benignity criterion is a proposition, which can be true or false, related to the variant, in connection with a first type or a second type condition, and wherein at least one of the aforesaid criteria refers to a first type condition, and at least another one of the criteria refers to a second type condition. A "first type condition" comprises a statistical condition and/or a previously known condition. A "second type condition" comprises a patient-specific condition. Each pathogenicity/benignity criterion is associated with a level of evidence, indicative of a condition or level of pathogenicity or benignity. The method then provides preparing (S2) input information (I) for a trained algorithm (A), trained using artificial intelligence and/or machine learning techniques. The input information (I) comprises, for each variant and for each level of evidence, information relative to the number of pathogenicity/benignity criteria associated with the level of evidence which are met by the variant. Finally, the method comprises processing the aforementioned input information by the trained algorithm (A), to obtain an output information (O) representative of the pathogenicity/benignity of each of the considered genomic variants. The algorithm (A) is trained in a preliminary step of training (S0), based on a training dataset of known cases, providing in input the input information (I0) calculated for the known cases, and training the algorithm based on the knowledge of the pathogenicity/benignity of the respective known cases.
This review starts off with the first germline homozygous variants of the Nucleoporin 98 gene (NUP98) in siblings whose clinical presentation recalls Rothmund-Thomson (RTS) and Werner (WS) syndromes. The progeroid phenotype caused by a gene associated with haematological malignancies and neurodegenerative disorders primed the search for interplay between caretakers involved in genome instability syndromes and Nuclear Pore Complex (NPC) components. In the context of basic information on NPC architecture and functions, we discuss the studies on the interdependence of caretakers and gatekeepers in WS and Hereditary Fibrosing Poikiloderma (POIKTMP), both entering in differential diagnosis with RTS. In WS, the WRN/WRNIP complex interacts with nucleoporins of the Y-complex and NDC1 altering NPC architecture. In POIKTMP, the mutated FAM111B, recruited by the Y-complex's SEC13 and NUP96, interacts with several Nups safeguarding NPC structure. The linkage of both defective caretakers to the NPC highlights the attempt to activate a repair hub at the nuclear periphery to restore the DNA damage. The two separate WS and POIKTMP syndromes are drawn close by the interaction of their damage sensors with the NPC and by the shared hallmark of short fragile telomeres disclosing a major role of both caretakers in telomere maintenance.
The focus of this study is to investigate the therapeutic benefit of autologous adipose-derived regenerative cells in patients with wrist arthritis. The hypothesis of this trial is that the use of adult-adipose derived regenerative cells as a treatment of wrist arthritis will induce healing and decrease pain compared to the control group. With adult-adipose derived regenerative cell administration, the medical practitioner would anticipate a reduction in inflammation, acceleration in healing, decreased pain in patients post procedure, and increased function and strength in the affected wrist. Currently, no clinical studies have been constructed to determine the efficacy of ADRCs in wrist arthritis patients.

Subjects will fall into two categories: treatment group (20) and control group (20 subjects). The treatment group will undergo a small liposuction procedure and receive wrist osteoarthritis treatment with an ultrasound-guided injection of 5 ml adipose-derived stem cells (ADSCs) into the wrist. The control group will receive a 5 ml cortisone injection into the wrist.
BACKGROUND: Access to medicines is one of the most serious public health problems globally, and Chile is not an exception. The aim of this study was to explore patients' perceptions, beneficiaries of both public and private health sectors, of barriers and facilitators in access to medicines in general, and those associated with the treatment of diabetes, dyslipidemia and hypertension.
METHODS: Ten focus groups of patients with these diseases, diagnosed for at least six months and with prescribed medication, were carried out in five regions of Chile: Arica (north), Aysén (south), and Valparaíso, Metropolitan, and Maule (center).
RESULTS: The experience of access to medicines is determined by the insurance system, the experience of care with public or private providers, and geographical-administrative difference between capital and other regions. Beneficiaries of public sector value territorial coverage of primary care, which guarantees access in isolated areas and, despite their greater socioeconomic vulnerability, perceive greater protection in access (access conditions, delivery reliability and adherence to pharmacological treatment). The main problem observed is the financing of treatments not covered by the system. Beneficiaries of private sector perceive that they have access to medicines of better quality than those provided free of charge by public sector, but raise fears associated with the inability to afford them and distrust in the market process. Regarding the type of provider, public sector shows greater capacity for user loyalty, which is expressed in regular visits and follow-up, unlike discontinuous examinations among private sector beneficiaries.
CONCLUSIONS: Different access conditions both at the territorial level and in the health subsystems are evident. It is necessary to make progress in addressing the problem of access to medicines in a comprehensive manner.
Surgeon Administered Group In the intra-operative cohort, the block will be administered after the final components are in place and cement debris is removed. The knee joint is irrigated with dilute hibiclens or betadine followed by pulsatile lavage per institutional protocol. A blunt tip 1.5in 18ga needle was then used to administer 15cc of 0.5% ropivocaine.. The location of the saphenous nerve as it exits the adductor canal will be estimated to be 1.5x the TEA proximal to the medial epicondyle in men and 1.3x the TEA proximal in women as described by Kavolus et al. The 60cc of the anesthetic will then injected through the vastus medialis musculature in a field extending from 1cm proximal to one cm distal to the assumed location of the nerve with the needle directed in from 20° to 45° medial. The wound is then irrigated pulsatile lavage one final time and closed in layered fashion.
The invention discloses a human single-chain antibody fragment (scFv) antibody of anti-recombination basic fibroblast growth factor and an application thereof. An amino acid sequence of heavy chain variable area of the human scFv antibody is shown in SEQ ID NO. 1, and an amino acid sequence of light chain variable area of the human scFv antibody is shown in SEQ ID NO. 2. A gene sequence encoding the heavy chain variable area is shown in SEQ ID NO. 3. A gene sequence encoding the light chain variable area is shown in SEQ ID NO. 4. The human scFv antibody has the characteristics of high affinity and specificity, and can be directly developed to be used as an antibody drug for human because the human scFv antibody is fully human antibody. The gene encoding the human scFv antibody can be constructed and expressed to obtain various forms of micromolecular genetic engineering antibodies, such as, fragment antigen-binding (Fab) antibody, F(ab)2, single chain antibody, Nanobody, antibody fusion protein, immunoglobulin G (IgG) complete antibody, etc., which can be used for preparing antibody drugs for diagnosing and treating tumor and/or inhibiting viscera fibrosis.
The patients received orally 200 mg Placebo per kg body weight divided in three doses per day in identically prepared capsules. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without Placebo respectively the groups were switched for another 6 months (period 2).
PURPOSE OF REVIEW: Tumor-informed circulating tumor DNA (ctDNA) is an emerging biomarker in urothelial carcinoma. Recent clinical trials have investigated the integration of ctDNA into clinical decision-making in patients with muscle-invasive bladder cancer, their findings suggest that ctDNA may potentially revolutionize the way we stratify patients to different treatment modalities.
RECENT FINDINGS: ctDNA informed from TURBT specimens was found to be prognostic of disease outcomes among patients with localized nonmetastatic bladder cancer. Detectable precystectomy ctDNA status was associated with worse survival outcomes. Additionally, ctDNA status was predictive of adverse disease on radical cystectomy, including the likelihood of disease upstaging, lymph node involvement, and having a locally advanced disease (≥pT3a). In the postcystectomy minimal residual disease (MRD) period, ctDNA status may refine patient selection to adjuvant therapy, and if validated by ongoing clinical trials, patients with undetectable postcystectomy ctDNA status may forgo adjuvant treatment, regardless of pathological stage. On the contrary, patients with pre or postcystectomy detectable ctDNA status may benefit from treatment intensification.
SUMMARY: The integration of ctDNA in clinical decision-making has the potential to revolutionize the way we manage urothelial carcinoma by refining patient selection to different treatment modalities. This approach could ultimately lead to personalization of oncological care, with the potential to reduce both treatment-related and financial toxicity.
Methylphenidate hydrochloride extended-release capsules are CNS stimulant.

Methylphenidate hydrochloride extended-release capsules is an extended-release formulation of methylphenidate for oral administration with a bi-modal release profile. Each bead-filled methylphenidate hydrochloride extended-release capsule contains half the dose as immediate-release beads and half as enteric-coated beads, thus providing an immediate release of methylphenidate and a second delayed release of methylphenidate.

The active substance in methylphenidate hydrochloride extended-release capsules is methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is

    Methylphenidate hydrochloride USP is a white, odorless, fine crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77 g/mol. 

Inactive ingredients: ammonio methacrylate copolymer, black iron oxide (10 and 40 mg capsules only), gelatin, methacrylic acid copolymer, polyethylene glycol, red iron oxide (10 and 40 mg capsules only), sugar spheres, talc, titanium dioxide, triethyl citrate, and yellow iron oxide (10, 30, and 40 mg capsules only).
The present invention belongs to the field of medical image analysis and relates to a method and system for monitoring, identifying, and analyzing jaundice based on image recognition. The present invention first analyzes the jaundice tendency index of the palm, foot, face, and body area images of the target object to determine whether the target object has jaundice. If it is determined that there is no jaundice, the target object's non jaundice patient identity is fed back. If it is determined that there is no jaundice, the target object's non jaundice patient identity is fed back. Otherwise, the target object's macular distribution characteristics, skin roughness characteristics, and sclera jaundice staining characteristics are further identified to verify the accuracy of the target object's jaundice disease diagnosis. If the verification result output is inconsistent, the target object's non jaundice patient identity is fed back. If the verification result output is consistent, the target object's jaundice patient identity is determined and the jaundice disease level of the target object is evaluated for feedback, To achieve comprehensive monitoring, identification, and accurate diagnosis of jaundice, and provide important technical support and improvement for medical services for jaundice patients.
A base for ointments and creams to be used in dermatology, and having to a very high degree, a capacity for hydration, contains 0.6-15 wt.% (pref. 1-10wt %) of the total wt., of microfibres with an extremely high specific surface area. The microfibres contain substances which act on the skin. Pref. they are of synthetic material, esp. polyethylene. The base contributes considerably to the hydration and smoothing of the skin. It can prevent the complete drying out of the cream which can occur with conventional bases containing water, fat, wetting agents, etc.
Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and/or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a cell-specific activator, e.g. IgE, cKIT, Fc RI, IL5R or CCR3. Binding of the bi-specific antibody to its targets results in the induction of an inhibitory pathway, through the inhibition of the signaling from the activator. Compositions and uses of the bi-specific complexes are also described.
Patients in group C will receive a dose of IV cefazolin every 8 hours for 24 hours (a total of 3 doses). Additionally, they will be instructed to take 5 days of oral cephalexin.
Implants will be placed at T0, then Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks then the impressions (indirect, closed tray echnique) shall be taken to fabricate the final crowns, then the final crowns will be fitted in place.
PROBLEM TO BE SOLVED: To provide an angiogenesis promoter, a method for promoting angiogenesis, an angiogenesis inhibitor, a method for inhibiting angiogenesis, and a method for screening an angiogenesis regulation composition in each of which novel genes involved in the mechanism of regulating angiogenesis are utilized.SOLUTION: The angiogenesis promoter comprises as an active ingredient a polynucleotide containing the base sequence shown in sequence No.1 (NCBI Accession No. AB044755) or a like polynucleotide, a polypeptide containing the amino acid sequence shown in sequence No.2 (NCBI Accession No. BAA96781) or a like polypeptide, an inhibitor of a polynucleotide containing the base sequence shown in sequence No.3 (NCBI Accession No. AB077880) or a like inhibitor, or an inhibitor of a polypeptide containing the amino acid sequence shown in sequence No.4 (NCBI Accession No. BAB83896) or a like inhibitor. The angiogenesis inhibitor comprises as an active ingredient an inhibitor of a polynucleotide containing the amino acid sequence shown in sequence No.1 (NCBI Accession No. AB044755) or a like inhibitor, an inhibitor of a polypeptide containing the amino acid sequence shown in sequence No.2 (NCBI Accession No. BAA96781) or a like inhibitor, a polynucleotide containing the base sequence shown in sequence No.3 (NCBI Accession No. AB077880) or a like polynucleotide, or a polypeptide containing the amino acid sequence shown in sequence No.4 (NCBI Accession No. BAB83896) or a like polypeptide.
During bacterial related sepsis, one of the key playing cells are macrophages, monocytes and T-lymphocytes (Hotchkiss et al., 2003). Macrophages and monocytes are supposed to be essential for the septic reaction to Gram-negative bacteria (Hotchkiss et al. 2003). Generally, there are two dominant types of macrophages: the pro-inflammatory M1 macrophage and the anti-inflammatory M2 macrophage (Mantovani et al., 2006). Similar to this macrophage characteristics, monocytes can also be categorized into pro-or anti-inflammatory. These macrophage/monocyte phenotypes can be differentiated in vitro from freshly isolated human blood monocytes using either GM-CSF giving raise to M1 macrophage/monocyte or M-CSF resulting in M2 macrophage/monocyte (Mantovani et al., 2006; Neu et al., 2013). Brunialti et al. (2012) have already demonstrated that the population of antiinflammatory M2 monocytes in septic patients is bigger than the pro-inflammatory M1 population. However, the authors did not further analyze the underlying mechanisms of M2 polarization nor did they identify the sepsis-causing pathogens.

In the present study, monocytes and macrophages of patients with Pseudomonas aeruginosa (PSA) sepsis are characterized by their surface marker expression profile via flow cytometry and cytokine pattern by ELISA in vivo and after ex-vivo LPS stimulation. In addition, an ex-vivo model system for PSA induced sepsis is validated. Blood of critically ill patients in the ICU infected with PSA is sampled to isolate peripheral blood mononuclear cells (PBMCs). Blood monocytes are analyzed for surface marker expression to determine the relative proportions of M1 and M2 monocytes in these patients and in healthy controls by flow cytometry
BACKGROUND: Ischemic heart disease (IHD) is a leading cause of morbidity and mortality worldwide, requiring innovative management strategies. Traditional disease management programs often struggle to maintain patient engagement and ensure long-term adherence to lifestyle modifications and treatment plans. Mobile health (mHealth) technologies have emerged as a promising approach to address these challenges by providing continuous, personalized support and monitoring. However, the reported use and effectiveness of mHealth in the management of chronic diseases, such as IHD, have not been fully explored.
OBJECTIVE: The primary aim of this study was to evaluate the feasibility and initial impact of an mHealth-based disease management program on coronary risk factors, specifically focusing on low-density lipoprotein cholesterol (LDL-C) levels, in individuals with chronic IHD. This formative study assessed changes in LDL-C and other metabolic health indicators over a 6-month period to determine the initial impact of the program on promoting cardiovascular health and lifestyle modification.
METHODS: This study was conducted using data from 266 individuals enrolled in an mHealth-based disease management program between December 2018 and October 2022. Eligibility was based on a documented history of IHD, with participants undergoing a comprehensive cardiac risk assessment before enrollment. The program included biweekly telephone sessions, health tracking via a smartphone app, and regular progress reports to physicians. The study measured change in LDL-C levels as the primary outcome, with secondary outcomes including body weight, triglyceride levels, and other metabolic health indicators. Statistical analysis used paired 2-tailed t tests and stratified analyses to assess the impact of the program.
RESULTS: Participants experienced a significant reduction in LDL-C, with LDL-C levels decreasing from a mean of 98.82 (SD 40.92) mg/dL to 86.62 (SD 39.86) mg/dL (P<.001). The intervention was particularly effective in individuals with high baseline LDL-C levels. Additional improvements were seen in body weight and triglyceride levels, suggesting a broader impact on metabolic health. Program adherence and engagement metrics suggested high participant satisfaction and compliance.
CONCLUSIONS: The results of this study suggest that the mHealth-based disease management program is feasible and has an initial positive impact on reducing LDL-C levels and improving metabolic health in individuals with chronic IHD. However, the study design does not allow for a definitive conclusion regarding whether mHealth-based disease management programs are more effective than traditional face-to-face care. Future studies are needed to further validate these findings and to examine the comparative effectiveness of these interventions in more detail.
Patients receive ipatasertib PO MTD on days 2-28 or 3-28 of cycle 1 and 1-28 of subsequent cycles. Patients also receive cisplatin IV weekly on day 1 of cycle 1, weeks 1-4 and day 1 of cycle 2, weeks 1-3 for 7 doses. Patients undergo RT daily (Monday-Friday) for 35 fractions during weeks 1-7. Treatment repeats every 28 days for a total of 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT, CT, or MRI during screening, follow-up, and as clinically indicated. Patients undergo blood sample collection and tumor biopsy on trial.
The invention improves a preparation technology of paeonol and bletilla polysaccharide microcapsules, aiming at the technical problems of low embedding rate of paeonol and high moisture of paeonol and bletilla polysaccharide clathrate compound product in the prior art. The preparation technology is improved by adopting physical microcapsule pelletizing. The preparation technology comprises concrete steps of: taking paeonol to dissolve by proper solvent, gradually dripping constant-temperature water solution of bletilla polysaccharide, homogenizing at high pressure, and drying by spray to obtain white powder, namely the paeonol and bletilla polysaccharide microcapsules. The embedding rate of the product produced by the method is obviously improved; the moisture of the product is reduced; the wall sticking phenomenon is improved; the product has stable bioactivity, can be produced and applied in a standard manner, and is significant in function, and convenient to use and store at the same time. The preparation technology can be used for developing cosmetic with the effects of sterilizing and diminishing inflammation, removing beverage and whitening, resisting wrinkle and moisturizing and the like. Meanwhile, application of the paeonol and bletilla polysaccharide microcapsules produced by the technology in the field of the cosmetic is within the protection range disclosed by the invention.